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MYC is one of the most frequently overexpressed
oncogenes in human cancer, and even modestly de-
regulated MYC can initiate ectopic proliferation in
many postmitotic cell types in vivo. Sensitization of
cells to apoptosis limits MYC’s oncogenic potential.
However, the mechanism through which MYC in-
duces apoptosis is controversial. Some studies
implicate p19ARF-mediated stabilization of p53, fol-
lowed by induction of proapoptotic BH3 proteins
NOXA and PUMA, whereas others argue for direct
regulation of BH3 proteins, especially BIM. Here,
we use a single experimental system to systemati-
cally evaluate the roles of p19ARF and BIM during
MYC-induced apoptosis, in vitro, in vivo, and in
combination with a widely used chemotherapeutic,
doxorubicin. We find a common specific requirement
for BIM during MYC-induced apoptosis in multiple
settings, which does not extend to the p53-respon-
sive BH3 family member PUMA, and find no evidence
of a role for p19ARF during MYC-induced apoptosis
in the tissues examined.
INTRODUCTION
Oncogene-induced tumor suppression presents an efficient cell-
autonomous restraint to tumor formation in the face of mitogenic
signaling by deregulated proto-oncogenes (Evan et al., 2005).
MYC serves as a paradigm example of this phenomenon (Askew
et al., 1991; Evan et al., 1992; Strasser et al., 1990): deregulated
MYC expression simultaneously drives both cell proliferation
and apoptosis, with the relative rates of each ultimately deter-
mining whether the affected population expands or contracts.
Importantly, the threshold level of MYC required to engage
apoptosis is set higher than the level required to initiate cell pro-Cell Reliferation, thereby enabling healthy cells to proliferate in response
to physiological signaling, all the while maintaining an effective
barrier to supraphysiological (i.e., oncogenic) MYC expression
(Murphy et al., 2008).
MYC-induced apoptosis is widely thought to be mediated by
the ARF-p53 pathway. Overexpression of MYC induces accu-
mulation of p19ARF (p14ARF in human cells), which counteracts
MDM2-mediated degradation of p53 (Kamijo et al., 1998; Stott
et al., 1998; Zindy et al., 1998; Eischen et al., 1999; Schmitt
et al., 1999). Activated p53 in turn induces apoptosis via tran-
scriptional upregulation of BH3-only proteins PUMA and NOXA
(Nakano and Vousden, 2001; Villunger et al., 2003). However,
apoptosis is not the only possible outcome from p53 stabiliza-
tion, and recent work has shown that acetylation of K117
(K120 in human p53) is also specifically required for induction
of NOXA, PUMA, and thereby apoptosis. Significantly, a
K117R mutant p53 is still competent to induce cell-cycle arrest,
senescence, and tumor suppression (Li et al., 2012). Thus, a
dual-signal mechanism governs cell fate in response to p53
accumulation. Additionally, several groups have reported
MYC-induced apoptosis in the absence of either p19ARF or
p53, strongly suggesting the existence of an alternative pathway
to MYC-induced killing (Hsu et al., 1995; Blyth et al., 2000; Ei-
schen et al., 2001; Finch et al., 2006).
A growing body of evidence supports a central role for the
BCL2 homologous (BH) family of proteins in mediating MYC-
induced apoptosis. This family of proteins is subdivided into anti-
apoptotic (e.g., BCL2, BCLXL, MCL1, and A1), proapoptotic
BH3-only (including BIM, BID, BAD, PUMA, and NOXA), and
effector BH3 proteins, BAX and BAK. In response to proapopto-
tic stimuli, BAX and BAK oligomerize to cause mitochondrial
outer membrane permeabilization, triggering release of cyto-
chrome c, SMAC/DIABLO, and consequent activation of effector
caspases (Sarosiek et al., 2013b; Czabotar et al., 2014). Antia-
poptotic BH family proteins buffer against pore formation,
whereas proapoptotic BH3-only proteins counteract this buff-
ering and, in some instances, can directly stimulate BAX/BAK
oligomerization (Llambi et al., 2011; Sarosiek et al., 2013a).ports 8, 1347–1353, September 11, 2014 ª2014 The Authors 1347
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Figure 1. P19ARF Is Dispensable for MYC-
Induced Apoptosis in the Intestine
(A) Representative images of TUNEL staining of
apoptotic cells in small and large intestine (SI and
LI, respectively) of mice of the indicated geno-
types, treated daily with Tam (50mg/kg) to activate
MycERT2 for 3 days. Scale bars, 100 mm.
(B) Quantification (mean ± SEM) of TUNEL-posi-
tive cells (percentage [%] of total) in the small
intestine of Tam-treated wild-type (WT) control
(n = 3), R26MER/MER (n = 3), R26MER/MER;Bim null
(n = 4), and R26MER/MER;Arf null (n = 3) mice.
(C) Quantification (mean ± SEM) of TUNEL-
positive cells in the large intestine of Tam-treated
wild-type control (n = 3), R26MER/MER (n = 3),
R26MER/MER;Bim null (n = 4), and R26MER/MER;Arf
null (n = 3) mice.
Two-tailed, unpaired t tests were used to deter-
mine statistical significance: **p < 0.01; ***p <
0.001; ns, not significant.
See also Figure S1.MYC-induced apoptosis requires BAX/BAK (Dansen et al., 2006;
Juin et al., 2002), release of cytochrome c (Juin et al., 1999), and
activation of effector caspases, contingent upon tonic signaling
through CD95 (Hueber et al., 1997), and is blocked by coexpres-
sion of antiapoptotic family proteins (Bissonnette et al., 1992;
Fanidi et al., 1992; Pelengaris et al., 2002). Conversely, MYC-
dependent suppression of BCLXL and BCL2 sensitizes cells to
g-irradiation-induced apoptosis (Eischen et al., 2001; Maclean
et al., 2003). The recent identification of BIM as a transcriptional
target of MYC suggests that this BH3-only protein may directly
mediate MYC’s proapoptotic signal (Campone et al., 2011; Lee
et al., 2013). MYC induces BIM accumulation in Burkitt’s lym-
phoma, and MYC point mutants that fail to induce BIM also fail
to induce apoptosis. Notably, such mutants are fully competent
to induce p19ARF, p53, and indeed accumulation of p21 down-
stream of p53 (Hemann et al., 2005). These observations promp-
ted us to reexamine the relative contributions of p19ARF and
BIM to MYC-induced apoptosis. We employed here a single
transgenic model to systematically evaluate MYC-induced
apoptosis in a variety of settings. Our data reveal that BIM is
the primary mediator of MYC-induced apoptosis in multiple solid
tissues.
RESULTS
BIM Is Required for MYC-Induced Apoptosis in the
Intestine
To investigate the mechanistic requirements of MYC-induced
apoptosis in multiple tissues, we used a previously described
Rosa26-MycERT2mouse line that ubiquitously expressesa latent,1348 Cell Reports 8, 1347–1353, September 11, 2014 ª2014 The Authorstamoxifen (Tam)-inducible, chimeric pro-
tein comprised of full-length human
c-MYC fused to a modified ligand-binding
domain from the human estrogen receptor
(MycERT2). DeregulatedMYC functioncan
thus be induced acutely in Rosa26-
MycERT2 mice by systemic injection ofTam. Owing to the relatively weak activity of the endogenous
Rosa26 promoter, the level of MycERT2 expressed is sufficient
to drive ectopic proliferation without triggering apoptosis in
most adult R26MER/MER tissues, with the exception of the small
and large intestine, wherein MycERT2 is expressed at somewhat
higher levels as comparedwith other tissues. Consequently, acti-
vation of MycERT2 in the intestine breaches the threshold level of
MYC deregulation required to drive apoptosis (Murphy et al.,
2008).
To assess the relative contributions of p19ARF and BIM to
MYC-induced apoptosis in these tissues, we interbred Rosa26-
MycERT2 mice with Cdkn2atm1(GFP)Cjs (ARF GFP) mice, wherein
GFP is inserted into exon 1b of the Cdkn2a locus, abrogating
p19ARF expression (Zindy et al., 2003), and Bcl2l11tm1.1Ast
(BIM/) mice (Bouillet et al., 1999), to generate R26MER/MER;
Arf GFP/GFP and R26MER/MER;Bim/ progeny, respectively.
MycERT2 was induced systemically in adult mice via daily injec-
tion with Tam for 3 days, by which time MYC-induced ectopic
proliferation peaks, as previously shown (Figure S1A) (Murphy
et al., 2008). Tissues were harvested within 24 hr of the final
injection, and apoptotic cells were identified by nuclear terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining (Figure 1). In the small intestine,MYC-induced apoptosis
is largely restricted to the crypt region andwasmodestly reduced
by Arf deletion. In the large intestine, where MYC-induced
apoptosis is more widely distributed, apoptosis was unaffected
by p19ARF loss. Deletion of Bim on the other hand abrogated
MYC-induced apoptosis in these two tissues.
BIM is thought to act primarily via broad antagonism of prosur-
vival BH3 family proteins including BCL2, BCLXL, and MCL1,
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Figure 2. Bim Is Required for MYC-Induced
Sensitization to Doxorubicin
(A) Representative images of TUNEL staining of
apoptotic cells in tissues of mice of the indicated
genotypes treated daily with Tam (50 mg/kg) for
3 days and doxorubicin (10 mg/kg) on the third
day. Scale bar, 50 mm.
(B) Quantification (mean ± SEM) of TUNEL-posi-
tive cells (percentage [%] of total) in the indicated
tissues of Tam-and-doxorubicin-treated R26WT/WT
control (n = 3), R26MER/MER (n = 3), R26MER/MER;
Bim null (n = 3), and R26MER/MER;Arf null (n = 5)
mice. Two-tailed, unpaired t tests were used to
determine statistical significance: *p < 0.05; **p <
0.01; ***p < 0.001; ns, not significant.
See also Figure S2.although direct activation of the effector BH3 protein BAX likely
contributes to BIM’s potency (Sarosiek et al., 2013a). PUMA is
the primary BH3-only effector of p53-mediated apoptosis in
the intestine (Yu et al., 2003). Like BIM, PUMA is a broad speci-
ficity antagonist of prosurvival BH3 proteins, and like BIM dele-
tion, PUMA deletion accelerates MYC-induced B cell lympho-
magenesis (Michalak et al., 2009). We asked therefore if loss of
PUMA (in Bbc3tm1Astmice) suppresses MYC-induced apoptosis
in the intestine. Acute activation of MycERT2 in R26MER/MER;
Puma/ mice revealed modestly reduced MYC-driven
apoptosis in the small intestine, relative to PUMA-replete con-
trols, whereas deletion of Puma had no effect on MYC-induced
apoptosis in the large intestine (Figures S1B–S1D). Thus, among
the proapoptotic BH3-only proteins, there is a specific require-
ment for BIM during MYC-induced apoptosis in these tissues.
BIMMediates Proapoptotic Signaling byMYC inMultiple
Tissues
The level of MycERT2 expressed in other tissues of R26MER/MER
mice is alone insufficient to breach the apoptotic threshold butCell Reports 8, 1347–1353, Sepdoes sensitize cells to additional proapo-
ptotic stimuli, such as doxorubicin (Mur-
phy et al., 2008). To determine if
subthreshold apoptotic signaling by
MYC is mediated by p19ARF or BIM,
we primed R26MER/MER;Arf GFP/GFP and
R26MER/MER;Bim/ mice by activating
MycERT2 for 3 days, then treated mice
with a dose of doxorubicin that alone fails
to drive apoptosis in most tissues. The
combination of deregulated MYC and
doxorubicin drove measurable apoptosis
in liver and pancreatic islets of Langer-
hans, and enhanced MYC-induced killing
in colonic epithelium (Figure 2). Again,
deletion of Bim abrogated the apoptotic
response in all three tissues, whereas
disruption of Arf had no effect. Deletion
of Puma protected all three tissues to
the same extent as Bim loss, confirming
the cooperative nature of death inresponse to these two proapoptotic stimuli (Figure S2A).
Notably, however, death induced by doxorubicin alone, confined
in these experiments to the small intestine, is unaffected by Bim
deletion but does require PUMA, as expected for a canonical
p53-mediated response to DNA damage (Figure S2B). More-
over, doxorubicin neither induces BIM nor augments MYC
induction of BIM protein, and Bim is not required for doxoru-
bicin-induced killing inmouse embryonic fibroblasts (MEFs) (Fig-
ures S2C and S2D). Thus, MYC and doxorubicin elicit apoptotic
signaling via induction of distinct proapoptotic BH3 family
proteins.
MYC Directly Regulates BIM Expression
Elevated expression of Bim-EL is evident in RNA and protein
derived from the small intestine of Tam-treated R26MER/MER
mice (Figures S3A and S3B). We generated MEFs from
Rosa26-MycERT2 mice and acutely activated MycERT2 with
4-hydroxy-tamoxifen (4-OHT) in vitro to determine if MYC
directly regulates Bim expression. Increased expression of
Bim-EL mRNA was found after 6 hr of MycERT2 activation andtember 11, 2014 ª2014 The Authors 1349
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Figure 3. MYC Directly Regulates BIM
Expression
(A) Upper panel: quantitative real-time PCR anal-
ysis on mRNA from R26MER/WT MEFs, treated with
4-OHT for the indicated durations (hours).Odc1, an
established MYC target, was used as a positive
control. Mean ± SEM is shown (n = 3). Lower panel
shows immunoblot of BIM-EL expression in a par-
allel time course. ODC, ornithine decarboxylase.
(B) ChIP-seq read counts documenting binding of
endogenous MYC to the promoter region of murine
Bcl2l11 encoding BIM. N262 denotes specifically
immunoprecipitated protein/DNA complexes. IgG,
immunoglobulin G.
(C) ChIP on R26MER/WT MEFs treated with or
without 4-OHT using IgG control or MYC antibody,
followed by quantitative real-time PCR with
primers amplifying the BIM promoter region and
control fragment.
(D and E) Early-passage (p < 5) R26MER/WT MEFs,
WT, or nullizygous for Bim or Arf were treated with
4-OHT (100 nm) for 30 hr under low (0.2%) serum
conditions. The graph shows the percentage of
cells stained positive for Annexin V only (black) or
both Annexin V and propidium iodide (red). Mean ±
SEM from representative experiments performed
in biological triplicate is shown. Consistent results
were obtained in MEFs derived from at least two
embryos for each genotype.
(F) Clonogenic assay on R26MER/MER;Bim null and
R26MER/MER;BimWT early-passage MEFs cultured
in growth media plus 100 nM OHT.
Two-tailed, unpaired t testswere used to determine
statistical significance: **p < 0.01; ***p < 0.001; ns,
not significant. See also Figures S3 and S4.was followed by clear accumulation of BIM-EL protein
(Figure 3A). Whole-genome chromatin immunoprecipitation-
coupled deep sequencing (ChIP-seq) analysis revealed 4-OHT-
induced binding of MycER to the BIM (BCL2L11) promoter in
human MCF10A cells, and constitutive occupation of the Bim
promoter by endogenous MYC in murine KPC pancreatic tumor
cells (Morton et al., 2010), comparable to binding at the canoni-
cal MYC target geneODC1 (Figures 3B and S3C). Gene-specific
ChIP with the N262 antibody, which recognizes both endoge-
nous murine MYC and exogenous MycERT2, revealed increased
occupancy of the Bim promoter in R26MER/WT MEFs in response
to 4-OHT (Figure 3C), whereas ChIP analysis in HeLa cells
confirmed binding of MYC to the human BIM promoter region
(Figure S3D), consistent with previous reports by Campone
et al. (2011) and Lee et al. (2013).1350 Cell Reports 8, 1347–1353, September 11, 2014 ª2014 The AuthorsActivation of MycERT2 in R26MER/WT
MEFs cultured in low serum rapidly
leads to apoptosis. We generated MEFs
from multiple R26MER/WT;Arf GFP/GFP and
R26MER/WT;Bim/ embryos to assess
the contribution of p19ARF and BIM to
MYC-induced apoptosis in this system,
and measured apoptosis 30 and 72 hr
after addition of 4-OHT to cells in low
serum. Again, deletion of Bim suppressedMYC-induced apoptosis, whereas deletion ofArf did not (Figures
3D, 3E, S3E, and S3F). Although serum deprivation alone did
induce low levels of BIM expression, further induction of BIM
by MYC was unaffected by serum levels (Figure S3G), and,
notably, Bim deletion had no effect on the basal level of
apoptosis induced by culturing MEFs in low serum. Moreover,
deletion of Bim suppressed MYC sensitization of MEFs cultured
in growth media to both g-irradiation- and ABT-737-induced
apoptosis (Figure S4), and Bim null MEFs showed increased clo-
nogenic survival in the presence of deregulatedMYC (Figure 3F).
A Threshold Level of BIM Is Required for MYC-Induced
Apoptosis
Activation of MycERT2 in heterozygous R26MER/WT mice fails
to induce enterocyte apoptosis, whereas apoptosis is readily
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Figure 4. BIM Is Dose Limiting for MYC-
Induced Apoptosis
(A) Representative images of TUNEL staining
of apoptotic cells in small and large intestine
(SI and LI, respectively) of mice of the indi-
cated genotypes, treated daily with Tam
(50 mg/kg) to activate MycERT2 for 3 days. Scale
bars, 100 mm.
(B) Quantification (mean ± SEM) of TUNEL-posi-
tive cells in the small intestine of Tam-treated
R26MER/MER (n = 3), R26MER/MER;Bim null (n = 4),
and R26MER/MER;Bim heterozygous (n = 3) mice.
(C) Quantification (mean ± SEM) of TUNEL-posi-
tive cells in the large intestine of Tam-treated
R26MER/MER (n = 3) R26MER/MER;Bim null (n = 4),
and R26MER/MER;Bim heterozygous (n = 3) mice.
Two-tailed, unpaired t tests were used to deter-
mine statistical significance: *p < 0.05; **p < 0.01;
***p < 0.001.detected in the same tissue of Tam-treated homozygous
R26MER/MER mice, indicating that a threshold level of MYC
deregulation is required for this effect (Murphy et al., 2008). We
therefore asked if reducing Bim expression would attenuate
the proapoptotic signal emanating from MYC deregulation to a
level below this threshold and thereby protect R26MER/MER intes-
tines from apoptosis. Comparing levels of apoptosis across
R26MER/MER;Bim/, R26MER/MER;Bim+/, and R26MER/MER;
BimWT mice, it is clear that haploinsufficiency for Bim rescues
R26MER/MER intestines from MYC-induced apoptosis (Figure 4).
This result is in broad agreement with a previous report that
haploinsufficiency for Bim accelerates MYC-induced lympho-
magenesis and supports a model where a threshold level of
BIM is required to mediate MYC’s apoptotic signal (Egle et al.,
2004).
DISCUSSION
We present here evidence that the BH3-only protein BIM is the
primary mediator of MYC-induced apoptosis in vivo and in vitro.
We show MYC binding to the BIM promoter, acutely elevating
BIM expression, and provide genetic evidence that BIM is
required for MYC-induced apoptosis under multiple circum-
stances and in multiple solid tissues. Strikingly, deletion of
Puma fails to phenocopy Bim deletion when apoptosis is
induced by MYC alone, despite the fact that loss of PUMA,
like loss of BIM, has been shown to accelerate MYC-induced
lymphomagenesis and despite similarities in their mechanism
of action (Egle et al., 2004; Czabotar et al., 2014). Conversely,
Bim deletion fails to phenocopy PUMA loss during doxoru-
bicin-induced apoptosis in the small intestine. However, bothCell Reports 8, 1347–1353, SepBIM and PUMA are required for the syn-
thetic induction of apoptosis driven by
the combination of MYC and doxorubicin
in tissues where either alone is insuffi-
cient to trigger cell death. The differential
sensitivities of various tissues to experi-
mental apoptotic stimuli are partly ex-plained by differences in MycERT2 expression levels (Murphy
et al., 2008) but also likely reflect the level of apoptotic priming
intrinsic to each tissue, where differential expression of specific
antiapoptotic BH3 proteins may determine the relative potency
of individual proapoptotic BH3 proteins (Ni Chonghaile et al.,
2011). Thus, these results argue for a model wherein individual
BH3-only proteins have evolved to transduce specific proapo-
ptotic signals yet can combine to overcome antiapoptotic
buffering.
Therapeutic Implications
MYC family oncogenes are among the most frequently overex-
pressed genes across a broad spectrum of human cancers.
Effective MYC-centric therapies could therefore have a
tremendous impact on cancer survival rates. Several strate-
gies to target MYC are being actively pursued, including
direct suppression of MYC protein (Soucek et al., 2008;
Popov et al., 2010), transcriptional suppression (Zuber et al.,
2011), and synthetic lethality (Goga et al., 2007; Liu et al.,
2012; Kemp and Grandori, 2013), and it is likely that com-
binatorial strategies will ultimately prove the most effective.
A rational strategy to exploit the intrinsic apoptotic potential
of MYC-overexpressing cells would complement these efforts
greatly. BH3 mimetics suppress lymphomagenesis in Em-
MYC mice, even in the absence of a functional p53 pathway
(Kelly et al., 2013, 2014). Given the prevalence of MYC
overexpression in human cancers, our data support the
approach of augmenting the intrinsic apoptotic response
through the use of BH3 mimetics and suggest that this strategy
may elicit therapeutic benefits in a spectrum of solid tumor
types.tember 11, 2014 ª2014 The Authors 1351
EXPERIMENTAL PROCEDURES
Genetically Engineered Mice and Mouse Procedures
Rosa26-MycERT2 (Murphy et al., 2008), Cdkn2atm1(GFP)Cjs (Arf GFP; NCI Mouse
Repository; Zindy et al., 2003), Bcl2l11tm1.1Ast (BimNull; Jackson Laboratory;
Bouillet et al., 1999), andBbc3tm1Ast (PumaNull; Jackson Laboratory, distributed
by Charles River; Villunger et al., 2003) mice were maintained on a C57/bl6
background, housed on a 12hr light cycle, and fed andwatered ad libitum. Pro-
cedures involving mice were performed in accordance with protocol numbers
AN 076148 (UCSF IACUC, USA) and 55.2-2531.01-30/11 (University ofWuerz-
burg, Germany) and Home Office license number 60/4183 (CRUK BICR, UK)
and approved by the local animal research committees at all three locations.
All treatments were performed onmice aged 8–12weeks. Tam (Sigma-Aldrich)
dissolved in peanut oil was administered once a day by intraperitoneal injection
for 3 days at 50 mg/kg. Doxorubicin (LC Laboratories) dissolved in 0.9% NaCl
was administered once by intraperitoneal injection at 10 mg/kg. Tissues were
fixed overnight in zinc-buffered formalin (Thermo Scientific; 5701ZF).
Immunohistochemistry
TUNEL staining was performed on paraffin-embedded sections (4 mm thick)
using the ApopTag peroxidase labeling kit (Millipore; S7100). An additional
blocking step (1% BSA for 1 hr at room temperature) was incorporated prior
to addition of peroxidase-conjugated antidigoxigenin. Tissues were counter-
stained in Gil 1 hematoxylin followed by blueing solution. For quantification,
the number of TUNEL-positive nuclei (pyknotic or intact) and the total number
of cells per 203 field were counted manually. Five representative fields per
tissue sample from each mouse were scored, yielding a percent apoptosis
value. Graphs represent the mean ± SEM percent apoptosis across number
(‘‘n’’) of mice as indicated in the figure legends.
ACCESSION NUMBERS
Complete ChIP-seq data sets can be accessed in the Gene Expression
Omnibus database under accession numbers GSE44672 (mouse) and
GSE59001 (human).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.07.057.
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